PPT-Myeloma: Symptoms to diagnosis

Can we do better Hospital name Date What is myeloma Cancer of plasma cells Leads to Bone infiltration fractures especially vertebral wedge fractures hypercalcaemia pain. Dr. Andrew Chantry. Senior Clinical Lecturer and Honorary Consultant in . Haematology. University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust. UKMF Autumn Educational Day ‘The evolving management of multiple myeloma and related plasma cell disorders’. Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . Ready for Prime Time?. DANA-FARBER . CANCER INSTITUTE. Nikhil C. Munshi, MD . Professor of Medicine . Harvard Medical School. Boston VA Healthcare System. Director . Basic and Correlative Sciences. Dana-Farber Cancer . Dr Matthew Jenner. Consultant Haematologist. Southampton General Hospital . UK Myeloma Forum Autumn Day. 12 November 2014. Introduction. Why define high risk myeloma?. 3. Patient expectations. Outcomes vary widely between different patients. Ruben Niesvizky. Myeloma Center. Myelomacenter.org. run9001@med.cornell.edu. Multiple Myeloma: Natural History of Disease. Durie B; International Myeloma Foundation. . Concise review of the disease and treatment options: multiple myeloma. 2011/2012 edition;. Rochester, Minnesota. Jacksonville, Florida. Multiple . Myeloma. Monitoring and Therapy. Angela Dispenzieri, M.D.. IMF Patient Workshop . November 4, 2014. . Mayo Clinic College of Medicine . Mayo Clinic Comprehensive Cancer Center. NICE Guideline. Published Feb 2016. Adults with myeloma (and plasma cell leukaemia). Excluded:. Monoclonal . gammopathy. of uncertain significance (MGUS). Amyloidosis. Solitary . plasmacytomas. Included:. new treatment in the horizon. Dr Amin . I. slam . MB, MRCP UK , FRCPath UK. Consultant haematologist and . H. aemato. -Oncologist. Southend University Hospital NHS Foundation trust. Myeloma patients support group meeting. Program Goals. Defining Multiple Myeloma. Case 1. Diagnostic Criteria. Multiple Myeloma Requiring Therapy. Cytogenetic Risk Features. Case 1 (cont). Newly Diagnosed Multiple Myeloma. NCCN. ®. . Therapy for Transplant-Eligible Patients. Part I: Smoldering Multiple Myeloma . and . Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma . Moderator: . Sagar. . Lonial. , MD. Panelists: . Jonathan Kaufman, MD and Ajay . Nooka. Vi Dao, MD, FRCPC. vdao@cancercare.mb.ca. Presenter Disclosure. Faculty: Vi Dao. Relationships with commercial interests: none. Mitigating Potential Bias. Not Applicable. Learning Objectives. Distinguish MGUS from multiple myeloma. Miss Georgia Stewart . Sheffield Myeloma Research Team. Department of Oncology and Metabolism. Faculty of Medicine Dentistry and Health . University of Sheffield, UK. Most Viruses have a preferential tropism for tumour cells. Myeloma Symposium 9/29/2018. Aric Hall, MD – Assistant Professor – UW School of Medicine & Public Health. Disclosures. I have no significant conflicts of interest to disclose. . I have no financial relationship with any institution profiting from pharmaceutical sales, diagnostic testing, or any type of medical technology. . Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma.